{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:42:16Z","timestamp":1781196136536,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Glomerular endotheliosis is the pathognomonic glomerular lesion in pre-eclampsia that has also been described in those taking tyrosine kinase inhibitors for cancer treatment. Ibrutinib is a Bruton\u2019s tyrosine kinase inhibitor used to treat chronic lymphocytic leukemia (CLL). We report the first known case of glomerular endotheliosis on kidney biopsy in a patient on ibrutinib monotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>The patient presented with acute on chronic kidney disease, proteinuria, low C3 and C4 and a high rheumatoid factor titer. A kidney biopsy was performed to confirm a preliminary diagnosis of membranoproliferative glomerulonephritis (MPGN), the most common glomerular disease in patients with CLL. Unexpectedly, the kidney biopsy showed pre-eclampsia-like lesions on light and electron microscopy: occlusion of glomerular peripheral capillary lumens by swollen reactive endothelial cells. Findings of glomerulonephritis were not seen, and there were no specific glomerular immune deposits by immunofluorescence or electron microscopy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CLL is known to cause glomerular lesions, mainly MPGN. There is increasing evidence that ibrutinib, a major treatment for CLL, can cause kidney disease, but the precise pathology is not characterized. We present a patient with CLL on ibrutinib with signs of glomerular endotheliosis. Based on the absence of CLL-induced kidney pathologies typically seen on the kidney biopsy and the non-selectivity of ibrutinib, we attributed the glomerular endotheliosis to ibrutinib. In pre-eclampsia, increased soluble fms-like tyrosine kinase 1 (sFlt1) levels induce endothelial dysfunction by decreasing vascular endothelial growth factor (VEGF). Ibrutinib has been demonstrated to have non-selective tyrosine kinase inhibition, including inhibition of VEGF receptor (VEGFR) and epidermal growth factor receptor (EGFR). VEGFR and EGFR inhibitors have recently been described in the literature to cause hypertension, proteinuria, and glomerular endotheliosis. Kidney biopsy should be performed in CLL patients on ibrutinib that present with acute kidney injury (AKI) or proteinuria to determine whether the clinical picture is attributable to the disease itself or a complication of the therapy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12882-022-02873-w","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T20:05:01Z","timestamp":1658606701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib"],"prefix":"10.1186","volume":"23","author":[{"given":"Amy","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia L.","family":"Ambruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur Akin","family":"Oto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"issue":"11","key":"2873_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","volume":"16","author":"F Bosch","year":"2019","unstructured":"Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16(11):684\u2013701.","journal-title":"Nat Rev Clin Oncol"},{"issue":"60","key":"2873_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bcmd.2016.05.009","volume":"1","author":"S Arora","year":"2016","unstructured":"Arora S, Levitan D, Regmi N, Sidhu G, Gupta R, Nicastri AD, Saggi SJ, Braverman A. Cryoglobulinemia in a patient with chronic lymphocytic leukemia\u2014a case report and review of literature of renal involvement in CLL. Blood Cells Mol Dis. 2016;1(60):7\u201311.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"2873_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1746-1596-6-99","volume":"6","author":"X Dou","year":"2011","unstructured":"Dou X, Hu H, Ju Y, Liu Y, Kang K, Zhou S, Chen W. Concurrent nephrotic syndrome and acute renal failure caused by chronic lymphocytic leukemia (CLL): a case report and literature review. Diagn Pathol. 2011;6(1):1\u20137.","journal-title":"Diagn Pathol"},{"issue":"2","key":"2873_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/13506120500107261","volume":"12","author":"R Ikee","year":"2005","unstructured":"Ikee R, Kobayashi S, Hemmi N, Suzuki S, Miura S. Amyloidosis associated with chronic lymphocytic leukemia. Amyloid. 2005;12(2):131\u20134.","journal-title":"Amyloid"},{"issue":"1","key":"2873_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/ki.1992.270","volume":"42","author":"B Moulin","year":"1992","unstructured":"Moulin B, Ronco PM, Mougenot B, Francois A, Fillastre JP, Mignon F. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int. 1992;42(1):127\u201335.","journal-title":"Kidney Int"},{"issue":"3","key":"2873_CR6","doi-asserted-by":"publisher","first-page":"e0119156","DOI":"10.1371\/journal.pone.0119156","volume":"10","author":"AL Poitou-Verkinder","year":"2015","unstructured":"Poitou-Verkinder AL, Francois A, Drieux F, Lepretre S, Legallicier B, Moulin B, Godin M, Guerrot D. The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia\/small lymphocytic lymphoma: a 25-year multicenter experience. PLoS ONE. 2015;10(3):e0119156.","journal-title":"PLoS ONE"},{"issue":"5","key":"2873_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/ckj\/sfy026","volume":"11","author":"R Wanchoo","year":"2018","unstructured":"Wanchoo R, Bernabe Ramirez C, Barrientos J, Jhaveri KD. Renal involvement in chronic lymphocytic leukemia. Clin Kidney J. 2018;11(5):670\u201380.","journal-title":"Clin Kidney J"},{"issue":"1","key":"2873_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med"},{"issue":"23","key":"2873_CR9","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396.","journal-title":"Blood"},{"issue":"29","key":"2873_CR10","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci. 2010;107(29):13075\u201380.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"2873_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/jpet.117.242909","volume":"363","author":"T Barf","year":"2017","unstructured":"Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240\u201352.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2873_CR12","doi-asserted-by":"publisher","first-page":"e0233089","DOI":"10.1371\/journal.pone.0233089","volume":"15","author":"MF Adasme","year":"2020","unstructured":"Adasme MF, Parisi D, Van Belle K, Salentin S, Haupt VJ, Jennings GS, Heinrich JC, Herman J, Sprangers B, Louat T, Moreau Y. Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor. PLoS ONE. 2020;15(5):e0233089.","journal-title":"PLoS ONE"},{"issue":"24","key":"2873_CR13","doi-asserted-by":"publisher","first-page":"39218","DOI":"10.18632\/oncotarget.16836","volume":"8","author":"L Ping","year":"2017","unstructured":"Ping L, Ding N, Shi Y, Feng L, Li J, Liu Y, Lin Y, Shi C, Wang X, Pan Z, Song Y. The Bruton\u2019s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget. 2017;8(24):39218.","journal-title":"Oncotarget"},{"issue":"139","key":"2873_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","volume":"1","author":"R Roskoski Jr","year":"2019","unstructured":"Roskoski R Jr. Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019;1(139):395\u2013411.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2873_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020(1):336\u201345.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"2","key":"2873_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40265-017-0695-3","volume":"77","author":"ED Deeks","year":"2017","unstructured":"Deeks ED. Ibrutinib: a review in chronic lymphocytic leukaemia. Drugs. 2017;77(2):225\u201336.","journal-title":"Drugs"},{"issue":"13","key":"2873_CR17","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2873_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","volume":"21","author":"V Sibaud","year":"2020","unstructured":"Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Dermatological toxicities of Bruton\u2019s tyrosine kinase inhibitors. Am J Clin Dermatol. 2020;21(6):799\u2013812.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"2873_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/0886022X.2021.1874985","volume":"43","author":"C Mark\u00f3th","year":"2021","unstructured":"Mark\u00f3th C, File I, Sz\u00e1sz R, Bidiga L, Balla J, M\u00e1tyus J. Ibrutinib-induced acute kidney injury via interstitial nephritis. Ren Fail. 2021;43(1):335\u20139.","journal-title":"Ren Fail"},{"issue":"7","key":"2873_CR20","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1177\/1078155220904406","volume":"26","author":"ZZ Brener","year":"2020","unstructured":"Brener ZZ, Brener H, Losev A. Bruton\u2019s tyrosine kinase inhibitors and the kidney: focus on ibrutinib. J Oncol Pharm Pract. 2020;26(7):1735\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"2873_CR21","doi-asserted-by":"publisher","first-page":"E223","DOI":"10.1002\/ajh.25546","volume":"94","author":"S Manohar","year":"2019","unstructured":"Manohar S, Bansal A, Wanchoo R, Sakhiya V, Lucia S, Jhaveri KD. Ibrutinib induced acute tubular injury: a case series and review of the literature. Am J Hematol. 2019;94(9):E223\u20135.","journal-title":"Am J Hematol"},{"issue":"6","key":"2873_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739\u201345.","journal-title":"Blood"},{"issue":"7","key":"2873_CR23","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1073\/pnas.83.7.2195","volume":"83","author":"FR Jirik","year":"1986","unstructured":"Jirik FR, Sorge J, Fong S, Heitzmann JG, Curd JG, Chen PP, Goldfien R, Carson DA. Cloning and sequence determination of a human rheumatoid factor light-chain gene. Proc Natl Acad Sci. 1986;83(7):2195\u20139.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"2873_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s13730-013-0068-z","volume":"2","author":"Y Oe","year":"2013","unstructured":"Oe Y, Joh K, Sato M, Taguma Y, Onishi Y, Nakayama K, Sato T. Proliferative glomerulonephritis with monoclonal IgM-\u03ba deposits in chronic lymphocytic leukemia\/small lymphocytic leukemia: case report and review of the literature. CEN case reports. 2013;2(2):222\u20137.","journal-title":"CEN case reports"},{"issue":"6","key":"2873_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.5414\/CNP70527","volume":"70","author":"R\u00dc Mutluay","year":"2008","unstructured":"Mutluay R\u00dc, Aki SZ, Erten YA, Konca C, Yagci M, Barit G, Sindel S. Membranoproliferative glomerulonephritis and light-chain nephropathy in association with chronic lymphocytic leukemia. Clin Nephrol. 2008;70(6):527\u201331.","journal-title":"Clin Nephrol"},{"issue":"1","key":"2873_CR26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4049\/jimmunol.154.1.413","volume":"154","author":"R Crouzier","year":"1995","unstructured":"Crouzier R, Martin T, Pasquali JL. Monoclonal IgM rheumatoid factor secreted by CD5-negative B cells during mixed cryoglobulinemia. evidence for somatic mutations and intraclonal diversity of the expressed VH region gene. J Immunol. 1995;154(1):413\u201321.","journal-title":"J Immunol"},{"issue":"9","key":"2873_CR27","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1073\/pnas.84.9.2916","volume":"84","author":"TJ Kipps","year":"1987","unstructured":"Kipps TJ, Fong S, Tomhave E, Chen PP, Goldfien RD, Carson DA. High-frequency expression of a conserved kappa light-chain variable-region gene in chronic lymphocytic leukemia. Proc Natl Acad Sci. 1987;84(9):2916\u201320.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"2873_CR28","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.4049\/jimmunol.151.12.7273","volume":"151","author":"R Kobayashi","year":"1993","unstructured":"Kobayashi R, Rassenti LZ, Meisenholder G, Carson DA, Kipps TJ. Autoantigen inhibits apoptosis of a human B cell leukemia that produces pathogenic rheumatoid factor. J Immunol. 1993;151(12):7273\u201383.","journal-title":"J Immunol"},{"issue":"1","key":"2873_CR29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4049\/jimmunol.151.1.473","volume":"151","author":"L Mantovani","year":"1993","unstructured":"Mantovani L, Wilder RL, Casali P. Human rheumatoid B-1a (CD5+ B) cells make somatically hypermutated high affinity IgM rheumatoid factors. J Immunol. 1993;151(1):473\u201388.","journal-title":"J Immunol"},{"issue":"1","key":"2873_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood-2006-03-012948","volume":"109","author":"K Stamatopoulos","year":"2007","unstructured":"Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, Belhoul L, Stella S, Stavroyianni N, Crespo M, Hadzidimitriou A. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood. 2007;109(1):259\u201370.","journal-title":"Blood"},{"issue":"2","key":"2873_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","volume":"55","author":"F Ravandi","year":"2006","unstructured":"Ravandi F, O\u2019Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006;55(2):197\u2013209.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2873_CR32","first-page":"489","volume":"60","author":"G F\u00fcst","year":"1985","unstructured":"F\u00fcst G, Czink E, Minh D, Miszlay Z, Varga L, Hollan SR. Depressed classical complement pathway activities in chronic lymphocytic leukaemia. Clin Exp Immunol. 1985;60(3):489.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2873_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0165-2478(87)90110-6","volume":"14","author":"G F\u00fcst","year":"1987","unstructured":"F\u00fcst G, Miszlay Z, Czink E, Varga L, Paloczi K, Szegedi G, Holl\u00e1n SR. C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance. Immunol Lett. 1987;14(3):255\u20139.","journal-title":"Immunol Lett"},{"issue":"1","key":"2873_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/ajh.2830190109","volume":"19","author":"ME Heath","year":"1985","unstructured":"Heath ME, Cheson BD. Defective complement activity in chronic lymphocytic leukemia. Am J Hematol. 1985;19(1):63\u201373.","journal-title":"Am J Hematol"},{"issue":"1","key":"2873_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2014.146","volume":"29","author":"O Middleton","year":"2015","unstructured":"Middleton O, Cosimo E, Dobbin E, McCaig AM, Clarke C, Brant AM, Leach MT, Michie AM, Wheadon H. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia. 2015;29(1):107\u201314.","journal-title":"Leukemia"},{"issue":"8","key":"2873_CR36","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1681\/ASN.2007020255","volume":"18","author":"IE Stillman","year":"2007","unstructured":"Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol. 2007;18(8):2281\u20134.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2873_CR37","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S0046-8177(97)90179-9","volume":"28","author":"NH Chow","year":"1997","unstructured":"Chow NH, Hsu PI, Lin XZ, Yang HB, Chan SH, Cheng KS, Huang SM, Su IJ. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol. 1997;28(6):698\u2013703.","journal-title":"Hum Pathol"},{"issue":"2","key":"2873_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/MNH.0000000000000105","volume":"24","author":"M Sircar","year":"2015","unstructured":"Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens. 2015;24(2):131\u20138.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"2873_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.critrevonc.2014.10.007","volume":"93","author":"LM Palma","year":"2015","unstructured":"Palma LM, Gehrke I, Kreuzer KA. Angiogenic factors in chronic lymphocytic leukaemia (CLL): where do we stand? Crit Rev Oncol Hematol. 2015;93(3):225\u201336.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"2873_CR40","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129\u201336.","journal-title":"N Engl J Med"},{"issue":"2","key":"2873_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ndt\/gft465","volume":"29","author":"C Vigneau","year":"2014","unstructured":"Vigneau C, Lorcy N, Dolley-Hitze T, Jouan F, Arlot-Bonnemains Y, Laguerre B, Verhoest G, Goujon JM, Belaud-Rotureau MA, Rioux-Leclercq N. All anti-vascular endothelial growth factor drugs can induce \u2018pre-eclampsia-like syndrome\u2019: a RARe study. Nephrol Dial Transplant. 2014;29(2):325\u201332.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2873_CR42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnci\/djm311","volume":"100","author":"TV Patel","year":"2008","unstructured":"Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008;100(4):282\u20134.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2873_CR43","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.ekir.2018.07.005","volume":"3","author":"S Latcha","year":"2018","unstructured":"Latcha S, Jaimes EA, Gutgarts V, Seshan S. Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib. Kidney Int Rep. 2018;3(6):1477\u201381.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"2873_CR44","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1161\/HYPERTENSIONAHA.108.113860","volume":"52","author":"WB Melenhorst","year":"2008","unstructured":"Melenhorst WB, Mulder GM, Xi QI, Hoenderop JG, Kimura K, Eguchi S, Van Goor H. Epidermal growth factor receptor signaling in the kidney: key roles in physiology and disease. Hypertension. 2008;52(6):987\u201393.","journal-title":"Hypertension"},{"issue":"4","key":"2873_CR45","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.yexcr.2008.08.005","volume":"315","author":"F Zeng","year":"2009","unstructured":"Zeng F, Singh AB, Harris RC. The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp Cell Res. 2009;315(4):602\u201310.","journal-title":"Exp Cell Res"},{"issue":"12","key":"2873_CR46","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655\u201369.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2873_CR47","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/cells10040869","volume":"10","author":"X Gu","year":"2021","unstructured":"Gu X, Zhang S, Zhang T. Abnormal crosstalk between endothelial cells and podocytes mediates tyrosine kinase inhibitor (TKI)-induced nephrotoxicity. Cells. 2021;10(4):869.","journal-title":"Cells"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02873-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02873-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02873-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T12:33:08Z","timestamp":1676205188000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02873-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2873"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02873-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed written consent was obtained from the patient for the publication of this case report and the accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CE is a member of the Editorial Board of the Cell Biology and Transport Physiology Section of BMC Nephrology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}